GlassScriptPhysician profile
Wadie Toma
NPI 1821163437
$21,475.45
in general payments reported to CMS, 2019-2025
44 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,629 · 2020: $2,122 · 2021: $1,797 · 2022: $3,304 · 2023: $3,581 · 2024: $3,393 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,429.15 |
| Education | $194.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,017.80 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,735.63 | 2019-2025 | Rinvoq, Skyrizi |
| Glaxosmithkline, LLC. | $2,165.50 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $2,108.43 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Horizon Therapeutics Plc | $1,574.95 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,177.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,164.03 | 2021-2025 | Saphnelo, Evusheld |
| Genzyme Corporation | $1,119.97 | 2019-2025 | |
| Pfizer INC. | $993.69 | 2019-2025 | |
| Ucb, INC. | $966.50 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $656.68 | 2019-2024 | Taltz, Olumiant |
| Genentech USA, INC. | $636.56 | 2019-2025 | Actemra |
| Ani Pharmaceuticals, INC. | $353.04 | 2023-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $304.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $299.76 | 2019-2025 | Orencia |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wadie Toma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.